Literature DB >> 24407959

Pentraxins and IgA share a binding hot-spot on FcαRI.

Jinghua Lu1, Kristopher D Marjon, Carolyn Mold, Lorraine Marnell, Terry W Du Clos, Peter Sun.   

Abstract

The pentraxins, C-reactive protein (CRP), and serum amyloid P component (SAP) have previously been shown to function as innate opsonins through interactions with Fcγ receptors. The molecular details of these interactions were elucidated by the crystal structure of SAP in complex with FcγRIIA. More recently, pentraxins were shown to bind and activate FcαRI (CD89), the receptor for IgA. Here, we used mutations of the receptor based on a docking model to further examine pentraxin recognition by FcαRI. The solution binding of pentraxins to six FcαRI alanine cluster mutants revealed that mutations Y35A and R82A, on the C-and F-strands of the D1 domain, respectively, markedly reduced receptor binding to CRP and SAP. These residues are in the IgA-binding site of the receptor, and thus, significantly affected receptor binding to IgA. The shared pentraxin and IgA-binding site on FcαRI is further supported by the results of a solution binding competition assay. In addition to the IgA-binding site, pentraxins appear to interact with a broader region of the receptor as the mutation in the C'-strand (R48A/E49A) enhanced pentraxin binding. Unlike Fcγ receptors, the H129A/I130A and R178A mutations on the BC- and FG-loops of D2 domain, respectively, had little effect on FcαRI binding to the pentraxins. In conclusion, our data suggest that the pentraxins recognize a similar site on FcαRI as IgA.
© 2014 The Protein Society.

Entities:  

Keywords:  competition; site-directed mutagenesis; surface plasmon resonance

Mesh:

Substances:

Year:  2014        PMID: 24407959      PMCID: PMC3970889          DOI: 10.1002/pro.2419

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  31 in total

1.  The structure of a human type III Fcgamma receptor in complex with Fc.

Authors:  S Radaev; S Motyka; W H Fridman; C Sautes-Fridman; P D Sun
Journal:  J Biol Chem       Date:  2001-01-31       Impact factor: 5.157

2.  Neutrophil lactoferrin release induced by IgA immune complexes differed from that induced by cross-linking of fcalpha receptors (FcalphaR) with a monoclonal antibody, MIP8a.

Authors:  W Zhang; B Bi; R G Oldroyd; P J Lachmann
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

Review 3.  The role of C-reactive protein in the resolution of bacterial infection.

Authors:  T W Du Clos; C Mold
Journal:  Curr Opin Infect Dis       Date:  2001-06       Impact factor: 4.915

4.  Crystal structure of Fcγ receptor I and its implication in high affinity γ-immunoglobulin binding.

Authors:  Jinghua Lu; Jeff L Ellsworth; Nels Hamacher; Si Won Oak; Peter D Sun
Journal:  J Biol Chem       Date:  2011-09-29       Impact factor: 5.157

5.  Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide.

Authors:  J E Volanakis; M H Kaplan
Journal:  Proc Soc Exp Biol Med       Date:  1971-02

6.  Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin.

Authors:  M H Kaplan; J E Volanakis
Journal:  J Immunol       Date:  1974-06       Impact factor: 5.422

7.  Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum.

Authors:  M B Pepys; A C Dash; R E Markham; H C Thomas; B D Williams; A Petrie
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

8.  Insights into IgA-mediated immune responses from the crystal structures of human FcalphaRI and its complex with IgA1-Fc.

Authors:  Andrew B Herr; Edward R Ballister; Pamela J Bjorkman
Journal:  Nature       Date:  2003-05-21       Impact factor: 49.962

Review 9.  IgA Fc receptors.

Authors:  Renato C Monteiro; Jan G J Van De Winkel
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

10.  Crystallization and preliminary crystallographic analysis of the extracellular fragment of FcalphaRI/CD89.

Authors:  Maojun Yang; Gang Xu; Shentao Li; Lei Sun; Ning Shi; Wenwen Zeng; Hai Pang; Wei Zhang; Zihe Rao
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2003-11-27
View more
  7 in total

Review 1.  IgA and FcαRI: Pathological Roles and Therapeutic Opportunities.

Authors:  Annelot Breedveld; Marjolein van Egmond
Journal:  Front Immunol       Date:  2019-03-22       Impact factor: 7.561

Review 2.  IgA: Structure, Function, and Developability.

Authors:  Patrícia de Sousa-Pereira; Jenny M Woof
Journal:  Antibodies (Basel)       Date:  2019-12-05

3.  C-Reactive Protein Enhances IgG-Mediated Cellular Destruction Through IgG-Fc Receptors in vitro.

Authors:  A Robin Temming; Matthias Tammes Buirs; Arthur E H Bentlage; Louise W Treffers; Hannah Feringa; Steven W de Taeye; Taco W Kuijpers; Sietse Q Nagelkerke; Giso Brasser; Juk Yee Mok; Wim J E van Esch; Timo K van den Berg; Theo Rispens; C Ellen van der Schoot; Gestur Vidarsson
Journal:  Front Immunol       Date:  2021-03-15       Impact factor: 7.561

Review 4.  Isotype selection for antibody-based cancer therapy.

Authors:  N Vukovic; A van Elsas; J S Verbeek; D M W Zaiss
Journal:  Clin Exp Immunol       Date:  2020-11-30       Impact factor: 5.732

Review 5.  The Development of Serum Amyloid P as a Possible Therapeutic.

Authors:  Darrell Pilling; Richard H Gomer
Journal:  Front Immunol       Date:  2018-10-16       Impact factor: 7.561

Review 6.  Pentraxins and Fc Receptor-Mediated Immune Responses.

Authors:  Jinghua Lu; Carolyn Mold; Terry W Du Clos; Peter D Sun
Journal:  Front Immunol       Date:  2018-11-13       Impact factor: 7.561

Review 7.  The Phagocytic Code Regulating Phagocytosis of Mammalian Cells.

Authors:  Tom O J Cockram; Jacob M Dundee; Alma S Popescu; Guy C Brown
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.